Oxervate®
Cenegermin-bkbj 0.002% · ophthalmic solution
Dry Eye/OSD
Approved uses
Neurotrophic keratitis
1 drop in the affected eye(s) 6 times daily at 2-hour intervals for 8 weeks
OFF-LABELNot in the FDA label for this product
Moderate-to-severe dry eye disease
1 drop TID x 4 weeks (phase 2 dose-ranging regimen; a BID arm was also studied)
RCT · missed primary endpoint
The phase 2 randomized, double-masked, vehicle-controlled dose-ranging trial (81 TID, 82 BID, 84 vehicle, including Sjogren dry eye) missed its primary endpoint: change in Schirmer I at week 4 did not differ from vehicle (TID difference 0.93 mm, 95% CI -1.47 to 3.32, P=0.078; BID 2.31 mm, 95% CI -0.08 to 4.70, P=0.066, 1-sided alpha 0.025). Symptom scores (SANDE) fell significantly with TID only, and the authors conclude that larger studies are warranted.
Contraindications
None listed in the label.
Ophthalmic solution 0.002% (20 mcg/mL), weekly carton of 7 multiple-dose 1 mL vials, co-packaged Delivery System Kit with 8 vial adapters, 45 pipettes, 45 sterile disinfectant wipes, 1 dose recording card
Recombinant human nerve growth factor produced in Escherichia coli. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons. It acts through specific high-affinity (TrkA) and low-affinity (p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.
Warnings & Precautions
- Eye discomfort: OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. Advise the patient to contact their doctor if a more serious eye reaction occurs.
- Use with contact lens: A therapeutic or corrective lens could theoretically limit distribution to the corneal lesion; remove before dosing and reinsert 15 minutes after.
- Storage and handling: Stored frozen at the pharmacy and dispensed in an insulated pack; the weekly carton must reach a refrigerator within 5 hours and is good for 14 days refrigerated. Do not refreeze.
Common Side Effects
- Ocular: Eye pain after instillation, about 16%, which may arise as corneal healing occurs.
- Ocular, 1% to 10%: Corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing.
- Systemic: Headache, 1% to 10%.
- Postmarketing: Eye irritation, blepharitis including eyelid margin crusting and eyelid edema, corneal neovascularization.
Pregnancy: No human data. Subcutaneous dosing in pregnant rats and rabbits through organogenesis produced no adverse fetal effects at clinically relevant doses, with a slight increase in post-implantation loss at 42 mcg/kg/day and above (267 times the maximum recommended human ophthalmic dose).
Lactation: No data on presence in human milk, effects on the breastfed infant, or milk production.
Safety and effectiveness have been established in the pediatric population, supported by adequate and well-controlled trials in adults with additional safety data in pediatric patients from 2 years of age and older.